Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the ...

Scientists have developed a test which successfully predicts whether cancer will resist common forms of chemotherapy ...

Seoul National University Hospital recently announced that it successfully performed the first high-level ovarian cancer ...

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer ...

A model with eight independent risk factors can predict the risk for deep vein thrombosis in patients with epithelial ovarian cancer.

The health concerns surrounding endocrine disruptors, such as phthalates, BPA and PFAS, can sound scary. But what we do know ...

A new test could transform the success rates of chemotherapy in cancer treatment in the UK. Scientists have developed a DNA ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

Inoviq has issued a lengthy response to the ASX's 'please explain' pertaining to the company's early-stage cancer work.

The Ridley-Tree Cancer Center just launched its new High-Risk Breast Clinic in Santa Barbara. The focus of the new clinic is to ...